Morgan Stanley raised the firm’s price target on Donaldson (DCI) to $69 from $65 and keeps an Underweight rating on the shares. The firm updated estimates and is rolling forward its valuation to FY26 and increasing share repurchase expectations, but remains Underweight following fiscal Q3 reporting as it continues to see risk to the Life Sciences growth strategy, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCI:
- Hold Rating on Donaldson Company Amid Bioprocessing Challenges and Market Uncertainties
- Donaldson price target raised to $78 from $76 at Baird
- Donaldson’s Business at Risk: How International Tariffs Could Impact Operations and Competitiveness
- Morning Movers: Signet Jewelers and Dollar General surge following Q1 results
- Donaldson Company Appoints New COO Amidst Strong Q3 Results